NEW YORK (AP) — Workday is cutting about 1,750 jobs, or 8.5% of its workforce. In a Wednesday memo to employees, published in a securities filing, Workday CEO Carl Eschenbach said the layoffs ...

Finance and human resources software company Workday is laying off 1,750 employees, essentially cutting down its total workforce by 8.5%. Workday CEO Carl Eschenbach said in a note to employees ...

PLEASANTON, Calif. -- Workday is cutting about 1,750 jobs, or 8.5% of its workforce. In a Wednesday memo to employees, published in a securities filing, Workday CEO Carl Eschenbach said the ...

(Bloomberg) -- Workday Inc. is cutting about 8.5% of its workforce, making it the latest technology company to begin 2025 with headcount reductions. The cuts will amount to about 1,750 workers ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

HR software platform Workday is laying off 1,750 employees, or 8.5% of its workforce, it has been announced. According to a memo circulated on Wednesday, the layoffs are necessary for long-term ...

Biopharmaceutical company GSK is growing its Massachusetts work force, announcing plans to move its vaccines research and development and infectious disease teams from suburban Maryland to ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...

The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK does not need a miracle cure — just some rest and rehabilitation. Investors, though, seem unwilling ...